Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959131 | 0.90 | MAPT (0.43) | MAPTALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL23457688 | 0.78 | CA1 (0.46) | MAPTALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL713488 | 0.78 | CA1 (0.46) | MAPTALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL7749952 | 0.76 | CA1 (0.50) | MAPTALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL8675518 | 0.73 | MAPT (0.43) | MAPTALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL9981915 | 0.72 | MAPT (0.39) | MAPTALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL2377502 | 0.69 | CA1 (0.39) | KMT2ACA1CA2CA4CYP3A4 | |
| SCHEMBL28218021 | 0.68 | MAPT (0.35) | MAPTALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL108518 | 0.68 | — | — | |
| SCHEMBL21247206 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108059599-B | Preparation method of Venetong key intermediate | 凯方医药科技(上海)有限公司 | 2020-08-21 | — | — | CN | disclosed |